Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM257 in Advanced HER2-positive Solid Tumors
NCT05320874Phase 1Not yet recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Apr 2022
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of KM257 in solid tumor (7 arms), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Maximum tolerated dose up to 3 weeks, Recommended phase 2 dose up to 3 weeks and 2 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
KM257
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05320874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320874.